Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis

Shu-Fen Sun, Guan-Chyun Lin, Chien-Wei Hsu, Huey-Shyan Lin, I-H Siu Liou, Shin-Yi Wu, Shu-Fen Sun, Guan-Chyun Lin, Chien-Wei Hsu, Huey-Shyan Lin, I-H Siu Liou, Shin-Yi Wu

Abstract

Intraarticular hyaluronan or platelet-rich plasma (PRP) is widely used in the treatment of knee osteoarthritis (OA). The efficacy of combined hyaluronan with PRP remained inconclusive. This study aimed to investigate the efficacy of combined a single crosslinked hyaluronan (HYAJOINT Plus) and a single PRP versus a single PRP in patients with knee OA. In a prospective randomized-controlled trial, 85 patients with knee OA (Kellgren-Lawrence 2) were randomized to receive a single intraarticular injection of HYAJOINT Plus (3 ml, 20 mg/ml) followed by 3 ml PRP (the combined-injection group, N = 43) or a single injection of 3 ml PRP (the one-injection group, N = 42). The primary outcome was the change from baseline in the visual analog scale (VAS) pain (0-00 mm) at 6 months. Secondary outcomes included The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, Likert Scale), Lequesne index, single leg stance test (SLS), use of rescue analgesics and patient satisfaction at 1, 3 and 6 months. Seventy-eight patients were available for the intention-to-treat analysis at 6 months. Both groups improved significantly in VAS pain, WOMAC, Lequesne index and SLS at each follow-up visit (p < 0.001). Patients receiving a single PRP experienced significantly greater improvements in VAS pain than patients receiving combined injections at 1-month follow-up (adjusted mean difference: - 5.6; p = 0.017). There were no significant between-group differences in several of the second outcomes at each follow-up visit, except the WOMAC-pain and WOMAC-stiffness scores favoring the one-injection group at 1 month (p = 0.025 and p = 0.011). However, at 6-month follow-up, the combined-injection group achieved significantly better VAS pain reduction (p = 0.020). No serious adverse events occurred following injections. In conclusion, either combined injections of HYAJOINT Plus and PRP or a single PRP alone was safe and effective for 6 months in patients with Kellgren-Lawrence 2 knee OA. Combined injections of HYAJOINT Plus and PRP achieved better VAS pain reduction than a single PRP at 6 months. The results indicating a long term benefit effect of a combination of HYAJOINT Plus and PRP in a particular subset of patients with moderate knee OA need to be replicated in larger trials.ClinicalTrials.gov number NCT04315103.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of participants through the trial, ITT intention-to-treat.
Figure 2
Figure 2
Graph showing that in patients with baseline VAS > 56.4 mm, those treated with one injection experienced a greater reduction in VAS pain than those treated with combined injections at 3-month follow-up.

References

    1. Colen S, Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: A systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012;26:257–268. doi: 10.1007/BF03261884.
    1. Moreland LW. Intraarticular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: Mechanisms of action. Arthr. Res. Ther. 2003;5:54–67. doi: 10.1186/ar623.
    1. Lisignoli G, et al. Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: Evidence for CD44 and CD54 (intercellular adhesion molecule 1) involvement. Arthritis. Rheum. 2001;44:1800–1807. doi: 10.1002/1529-0131(200108)44:8<1800::AID-ART317>;2-1.
    1. Zhang W, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr. Cartil. 2008;16:137–162. doi: 10.1016/j.joca.2007.12.013.
    1. Sun SF, et al. Comparison of single intra-articular injection of novel hyaluronan (HYA-JOINT Plus) with Synvisc-One for knee osteoarthritis. J. Bone Jt. Surg. Am. 2017;99:462–471. doi: 10.2106/JBJS.16.00469.
    1. Tuan S, et al. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel crosslinked hyaluronic acid in the treatment of the knee osteoarthritis. J. Back Musculoskelet. Rehabil. 2018;31:709–718. doi: 10.3233/BMR-170950.
    1. Cugat R, et al. Biologic enhancement of cartilage repair: The role of platelet-rich plasma and other commercially available growth factors. Arthroscopy. 2015;31:777–783. doi: 10.1016/j.arthro.2014.11.031.
    1. Anitua E, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology. 2007;46:1769–1772. doi: 10.1093/rheumatology/kem234.
    1. Chang KV, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: A systematic review and meta-analysis. Arch. Phys. Med. Rehabil. 2014;95:562–575. doi: 10.1016/j.apmr.2013.11.006.
    1. Zhu Y, et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: A review. Osteoarthritis Cartil. 2013;21:1627–1637. doi: 10.1016/j.joca.2013.07.017.
    1. Görmeli G, et al. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: A randomized, double-blind, placebo-controlled trial. Knee Surg. Sport Traumatol. Arthrosc. 2017;25:958–965. doi: 10.1007/s00167-015-3705-6.
    1. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double-blind, randomized trial. Am. J. Sports Med. 2013;41:356–364. doi: 10.1177/0363546512471299.
    1. Martini LI, et al. Single platelet-rich plasma Injection for early stage of osteoarthritis of the knee. Joints. 2017;5:2–6. doi: 10.1055/s-0037-1601405.
    1. Buendía-López D, Medina-Quirós M, Fernández-Villacañas Marín MÁ. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acidinjection and daily NSAID administration with a 52-week follow-up: A randomized controlled trial. J. Orthop. Traumatol. 2018;19:3. doi: 10.1186/s10195-018-0501-3.
    1. Andia I, Abate M. Knee osteoarthritis: Hyaluronic acid, platelet-rich plasma or both in association? Expert. Opin. Biol. Ther. 2014;14:635–649. doi: 10.1517/14712598.2014.889677.
    1. Chen WH, et al. Synergistic anabolic actions of hyaluronic acid and platelet-rich plasma on cartilage regeneration in osteoarthritis therapy. Biomaterials. 2014;35:9599–9607. doi: 10.1016/j.biomaterials.2014.07.058.
    1. Russo F, et al. Platelet rich plasma and hyaluronic acid blend for the treatment of osteoarthritis: Rheological and biological evaluation. PLoS ONE. 2016;11:e0157048. doi: 10.1371/journal.pone.0157048.
    1. Anitua E, Sanchez M, De la Fuente M, Zalduendo MM, Orive G. Plasma rich in growth factors stimulates tendon and synovial fibroblast migration and biological properties of HA. Knee Surg. Sports Traumatol Arthrosc. 2012;20:1657–1665. doi: 10.1007/s00167-011-1697-4.
    1. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004;34:665–671. doi: 10.1016/j.bone.2003.12.010.
    1. Huskisson EC. Measurement of pain. Lancet. 1974;2:1127–1131. doi: 10.1016/S0140-6736(74)90884-8.
    1. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): A review of its utility and measurement properties. Arthritis. Care Res. 2001;45:453–461. doi: 10.1002/1529-0131(200110)45:5<453::AID-ART365>;2-W.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important relevant patient outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988;15:1833–1840.
    1. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: Validation-value in comparison with other assessment tests. Scand. J. Rheumatol. Suppl. 1987;65:85–89. doi: 10.3109/03009748709102182.
    1. Bohannon RW, Larkin PA, Cook AC, Gear J, Singer J. Decrease in timed balance scores with aging. Phys. Ther. 1984;64:1067–1070. doi: 10.1093/ptj/64.7.1067.
    1. Dworkin DH, et al. Consensus statement: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain. 2008;9:105–121. doi: 10.1016/j.jpain.2007.09.005.
    1. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis. Rheum. 2001;45:384–391. doi: 10.1002/1529-0131(200108)45:4<384::AID-ART352>;2-0.
    1. Sánchez M, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28:1070–1078. doi: 10.1016/j.arthro.2012.05.011.
    1. Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J. Rheumatol. 1997;24:779–781.
    1. Hassan B, Mockett S, Doherty M. Static postural sway, proprioception, and maximal voluntary quadriceps contraction in patients with knee osteoarthritis and normal control subjects. Ann. Rheum. Dis. 2001;60:612–618. doi: 10.1136/ard.60.6.612.
    1. Fisher NM, Pendergast DR. Reduced muscle function in patients with osteoarthritis. Scand. J. Rehabil. Med. 1997;29:213–221.
    1. Abate A, Verna S, Schiavone C, Di Gregorio P, Salini V. Efficacy and safety profile of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results) Eur. J. Orthop. Surg. Traumatol. 2015;25:1321–1326. doi: 10.1007/s00590-015-1693-3.
    1. Guo Y, et al. Treatment of knee osteoarthritis with platelet-richplasma plus hyaluronic acid in comparison with platelet-rich plasma only. Int. J. Clin. Exp. Med. 2016;9:12085–12090.
    1. Nasser ET. Treatment of knee osteoarthritis with platelet-rich plasma in comparison with platelet-rich plasma plus hyaluronic acid: A short-term double-blind randomized clinical study. Egypt Orthop J. 2018;53:31–37. doi: 10.4103/eoj.eoj_13_18.
    1. Dallari D, et al. Ultrasound-guided injection of platelet-rich plasma and hyaluronic acid, separately and in combination for hip osteoarthritis: A randomized controlled study. Am. J. Sports Med. 2016;44:664–671. doi: 10.1177/0363546515620383.
    1. Lana JF, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J. Stem Cells Regen. Med. 2016;12:69–78. doi: 10.46582/jsrm.1202011.
    1. Marmotti A, et al. One-step osteochondral repair with cartilage fragments in a composite scaffold. Knee Surg. Sports Traumatol. Arthrosc. 2012;20:2590–2601. doi: 10.1007/s00167-012-1920-y.
    1. Saturveithan C, et al. Intra-articular hyaluronic acid (HA) and platelet rich plasma (PRP) injection versus hyaluronic acid (HA) injection alone in patients with grade III and IV knee osteoarthritis (OA): A retrospective study on functional outcome. Malays. Orthop. J. 2016;10:35–40. doi: 10.5704/MOJ.1607.007.
    1. Zhao J, et al. Effects and safety of the combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) in the treatment of knee osteoarthritis: A systematic review and meta-analysis. BMC Musculoskelet. Disord. 2020;21:224. doi: 10.1186/s12891-020-03262-w.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する